Malignant Tumors of the Nasal Cavity
No Results
No Results
processing….
Sinonasal malignant neoplasms are rare tumors that constitute about 3% of tumors in the upper respiratory tract. Only a fraction arises at the nasal cavity. [1] Due to the contiguity of the nasal cavities with the paranasal sinuses, identifying the specific site of origin of large sinonasal tumors is often difficult. Hence, malignant tumors of the nasal cavities are often grouped with those of the paranasal sinuses. Their proximity to vital structures such as the brain, optic nerves, and internal carotid artery pose significant challenges for their treatment and may be the source of significant morbidity to the patients. Malignant tumors of the sinonasal tract are derived from diverse histologic elements within the nasal cavity. They include the following:
See the list below:
Transitional cell carcinoma
Adenocarcinoma
Adenoid cystic carcinoma
Olfactory neuroblastoma
Undifferentiated carcinoma
See the list below:
Soft-tissue sarcoma
Leiomyosarcoma
Myxosarcoma
Hemangiopericytoma
Connective tissue sarcoma
Synovial sarcoma
See the list below:
Lymphoma
Plasmacytoma
Metastatic carcinoma
The annual incidence of nasal tumors in the United States is estimated to be less than 1 in 100,000 people per year. These tumors occur most commonly in whites, and the incidence in males is twice that of females. [2] Epithelial tumors most commonly present in the fifth and sixth decades of age.
Although tumors of the nasal cavities are equally divided between benign and malignant types, most tumors of the paranasal sinuses are malignant. Approximately 55% of sinonasal tumors originate from the maxillary sinuses, 35% from the nasal cavities, 9% from the ethmoid sinuses, and the remainder from the frontal and sphenoid sinuses. Squamous cell carcinoma is the most common malignant histologic type (approximately 70-80%) followed by adenoid cystic carcinoma and adenocarcinoma (approximately 10% each). [3]
A study by Gerth et al reported the overall incidence of malignant pediatric sinonasal tumors in the United States to be 0.052 per 100,000. The study, which utilized the Surveillance, Epidemiology, and End Results (SEER) database, found that rhabdomyosarcoma was the most frequently occurring malignancy among patients below age 20 years. [4]
Exposures to industrial fumes, wood dust, nickel refining, and leather tanning have all been implicated in the carcinogenesis of various types of sinonasal malignant tumors. In particular, wood dust and leather tanning exposures are well associated with increased risk for adenocarcinoma. [5] Other etiologic agents have been reported including mineral oils, chromium and chromium compounds, isopropyl oils, lacquer paint, soldering and welding, and radium dial painting. Tobacco smoking is not considered to be a significant etiologic factor; however, recent studies demonstrated a higher incidence of nasal cancers in cigarette smokers. [2, 6]
Tumors of the sinonasal tract commonly present with symptoms that are identical to those caused by inflammatory sinus disease, such as nasal obstruction, nasal discharge, epistaxis, headache, facial pain, and nasal discharge. Tumors of nasal cavities, however, tend to be diagnosed earlier than those of the paranasal sinuses because of the earlier presentation of obstructive symptoms and epistaxis.
To further complicate this issue, 9-12% of patients are frequently asymptomatic. [7] These factors contribute to a delay in diagnoses, and, hence, an advanced stage of disease at the time of diagnosis. Patients with unilateral sinonasal symptoms or those that are associated with unilateral facial swelling, diplopia or blurred vision, unilateral proptosis, and cranial neuropathies should raise a high index of suspicion for sinonasal cancer and warrant urgent evaluation.
Regional and distant metastases are infrequent even in the presence of advanced stage tumors. The incidence of cervical metastases on initial presentation varies from 1-26%, with most large series reporting less than 10%. Distant metastasis on initial presentation is even less common, with most series presenting an incidence of less than 7%. [1] The presence of regional or distant metastases is a poor prognostic sign.
A thorough head and neck examination, cranial nerve assessment, and a nasal endoscopy should be performed in all patients. Physical examination may reveal proptosis, extraocular muscle impairment, mass effect of the cheek, gingival or gingivobuccal sulcus, (eg, ill-fitting dentures) and loose dentition. Numbness or hyperesthesia of the infraorbital (V2) branch of the maxillary nerve strongly suggests malignant invasion (as in the images below).
By examining the close relationships of the nasal cavities to the oral cavity, paranasal sinuses, orbit, nasopharynx, pterygomaxillary fissure and pterygopalatine fossa, infratemporal fossa, skull base, and intracranial fossa, one can better understand the myriad signs and symptoms caused by sinonasal tumors.
Local tumor invasion can breach the boundaries of the nasal cavity invading and destroying structures and/or following preformed pathways. The paired nasal cavities are separated by the nasal septum. Their lateral walls comprise the medial wall of the maxillary sinus and the inferior, middle, and superior turbinates. Lateral extension of tumor can infiltrate the maxillary sinus, ethmoid air cells, or even the orbit (through the lamina papyracea). Eventually, orbital involvement manifests as ocular pain, fullness of the eyelid, unilateral epiphora, diplopia, extraocular muscle limitation/diplopia, or proptosis. The floor of the nasal cavity corresponds to the hard palate of the oral cavity; thus, caudal extension of the tumor can present as palatal fullness, pain, and ulceration.
The roof of the nasal cavities is formed by the cribriform plate, which separates the dura of the anterior cranial fossa from the nasal cavity. The cribriform plate, as implied by its name, has multiple openings to accommodate the passage of olfactory filaments. Tumor can spread to the anterior cranial fossa using these openings or by perineural spread. Violation of this barrier during surgery is likely to produce a cerebrospinal fluid (CSF) leak, increasing the risk for meningitis and intracranial abscess. The nasal cavities open externally via the nares and communicate posteriorly with the nasopharynx via the choanae. The eustachian tubes open into the nasopharynx just behind the infero-lateral aspect of the choanae. Tumor extension into the nasopharynx may cause eustachian tube obstruction and secondary serous otitis media that manifests as hearing loss.
Except in the nasal vestibule, the nasal cavity is lined with pseudostratified columnar ciliated epithelium. The nasal vestibule, which corresponds to the ala of the nose, is lined with squamous epithelium containing vibrissae and sweat and sebaceous glands. A small part of the superior portion of the nasal cavity (bound by the superior turbinate laterally and the nasal septum medially) is lined by olfactory epithelium.
The pterygopalatine and infratemporal fossae are important anatomical considerations, as they are densely populated by the mastication muscles, various sensory and motor nerves, and by the blood vessels that supply the nasal cavity, oral cavity, maxillary teeth, pharynx, and ICAs. Tumor extension into these areas can cause a myriad of symptoms, such as the following:
Trismus (involvement of the pterygoid muscles or motor branches of the mandibular division of the trigeminal nerve)
Facial hypesthesia (involvement of the infraorbital nerve or other sensory branches from the maxillary and mandibular divisions of the trigeminal nerve)
Pain in the maxillary dentition (involvement of the anterior, middle, or posterior superior alveolar nerve branches of the maxillary division of the trigeminal nerve)
Severe epistaxis (involvement of the terminal branches of the internal maxillary artery)
The pterygopalatine and infratemporal fossae are also potential routes for intracranial tumor spread, via direct extension or hematogenous spread.
A retrospective study by Stepan et al of adult patients with sinonasal rhabdomyosarcoma found a 5-year overall survival rate of 28.4%, with better survival found in patients 35 years or younger at diagnosis (31.9% vs 24.4% for patients over age 35 years). The investigators noted that the 5-year overall survival rate between alveolar and embryonal subtypes (30.5% vs 41.6%, respectively) did not differ by a statistically significant amount but that patients with metastatic disease had worse 5-year overall survival compared with those without (14.7% vs 33.9%, respectively). [8]
Zimmer LA, Carrau RL. Neoplasms of the nose and paranasal sinuses. Bailey BJ, Johnson JT, Newland SD, eds. Head & Neck Surgery – Otolaryngology. 4th. Lippincott, Williams & Wilkins; 2006.
Caplan LS, Hall I, Levine RS, Zhu K. Preventable risk factors for nasal cancer. Ann Epidemiol. 2000. 10:186-91.
Weymuller EA, Gal TJ. Neoplasms of the nasal cavity. Cummings CW, Flint PW, Harker LA et al. eds. Otolaryngology – Head and Neck surgery. 4th. Mosby; 2005.
Gerth DJ, Tashiro J, Thaller SR. Pediatric sinonasal tumors in the United States: incidence and outcomes. J Surg Res. 2014 Jul. 190 (1):214-20. [Medline].
d’Errico A, Pasian S, Baratti A, et al. A case-controlled study on occupational risk factors for sino-nasal cancer. Occup Environ Med. 2009. 66:448-55.
Benninger MS. The impact of cigarette smoking and environmental tobacco smoke on nasal and sinus disease: a review of the literature. Am J Rhinol. 1999 Nov-Dec. 13(6):435-8. [Medline].
Jackson RT, Fitz-Hugh GS, Constable WC. Malignant neoplasms of the nasal cavities and paranasal sinuses: (a retrospective study). Laryngoscope. 1977 May. 87(5 Pt 1):726-36. [Medline].
Stepan K, Konuthula N, Khan M, et al. Outcomes in Adult Sinonasal Rhabdomyosarcoma. Otolaryngol Head Neck Surg. 2017 Jul. 157 (1):135-41. [Medline].
Sasaki M, Eida S, Sumi M, Nakamura T. Apparent diffusion coefficient mapping for sinonasal diseases: differentiation of benign and malignant lesions. AJNR Am J Neuroradiol. 2011 Jun. 32(6):1100-6. [Medline].
Snyderman CH, Carrau RL, deVries EJ. Johnson JT, Derkay CS, Mandell-Brown MK, Newman RK eds. Carotid artery resection: update on preoperative evaluation. Mosby; 1993. 6: 341-4.
Mansell NJ, Bates GJ. The inverted Schneiderian papilloma: a review and literature report of 43 new cases. Rhinology. 2000 Sep. 38(3):97-101. [Medline].
Schlosser RJ, Mason JC, Gross CW. Aggressive endoscopic resection of inverted papilloma: an update. Otolaryngol Head Neck Surg. 2001 Jul. 125(1):49-53. [Medline].
Kraft M, Simmen D, Kaufmann T, Holzmann D. Long-term results of endonasal sinus surgery in sinonasal papillomas. Laryngoscope. 2003 Sep. 113(9):1541-7. [Medline].
Nicolai P, Villaret AB, Bottazzoli M, Rossi E, Valsecchi MG. Ethmoid Adenocarcinoma–From Craniofacial to Endoscopic Resections: A Single-Institution Experience over 25 Years. Otolaryngol Head Neck Surg. 2011 Aug. 145(2):330-7. [Medline].
Hanna EYN, Westfall C. Cancer of the nasal cavity, paranasal sinuses and orbit. Myers EN, Suen JY, Myers JN, Hanna EYN, eds. Cancer of the head and neck. 4th. Saunders; 2003.
Barnes L. Surgical pathology of the head and neck. 2nd. Marcel Dekker; 2001.
Kida A, Endo S, Iida H, et al. Clinical assessment of squamous cell carcinoma of the nasal cavity proper. Auris Nasus Larynx. 1995. 22(3):172-7. [Medline].
Heffner DK, Hyams VJ, Hauck KW, Lingeman C. Low-grade adenocarcinoma of the nasal cavity and paranasal sinuses. Cancer. 1982 Jul 15. 50(2):312-22. [Medline].
Van Gerven L, Jorissen M, Nuyts S, Hermans R, Vander Poorten V. Long-term follow-up of 44 patients with adenocarcinoma of the nasal cavity and sinuses primarily treated with endoscopic resection followed by radiotherapy. Head Neck. 2011 Jun. 33(6):898-904. [Medline].
Claus F, Boterberg T, Ost P, et al. Postoperative radiotherapy for adenocarcinoma of the ethmoid sinuses: treatment results for 47 patients. Int J Radiat Oncol Biol Phys. 2002 Nov 15. 54(4):1089-94. [Medline].
Lund VJ, Chisholm EJ, Takes RP, et al. Evidence for treatment strategies in sinonasal adenocarcinoma. Head Neck. 2012 Aug. 34(8):1168-78. [Medline].
Knegt PP, Ah-See KW, vd Velden LA, Kerrebijn J. Adenocarcinoma of the ethmoidal sinus complex: surgical debulking and topical fluorouracil may be the optimal treatment. Arch Otolaryngol Head Neck Surg. 2001 Feb. 127(2):141-6. [Medline].
Almeyda R, Capper J. Is surgical debridement and topical 5 fluorouracil the optimum treatment for woodworkers’ adenocarcinoma of the ethmoid sinuses? A case-controlled study of a 20-year experience. Clin Otolaryngol. 2008 Oct. 33(5):435-41. [Medline].
Rhee CS, Won TB, Lee CH, et al. Adenoid cystic carcinoma of the sinonasal tract: treatment results. Laryngoscope. 2006 Jun. 116(6):982-6. [Medline].
Lupinetti AD, Roberts DB, Williams MD, et al. Sinonasal adenoid cystic carcinoma: the M. D. Anderson Cancer Center experience. Cancer. 2007 Dec 15. 110(12):2726-31. [Medline].
Szanto PA, Luna MA, Tortoledo ME, White RA. Histologic grading of adenoid cystic carcinoma of the salivary glands. Cancer. 1984 Sep 15. 54(6):1062-9. [Medline].
Spiro RH. Distant metastasis in adenoid cystic carcinoma of salivary origin. Am J Surg. 1997 Nov. 174(5):495-8. [Medline].
Frierson HF Jr, Mills SE, Fechner RE, Taxy JB, Levine PA. Sinonasal undifferentiated carcinoma. An aggressive neoplasm derived from schneiderian epithelium and distinct from olfactory neuroblastoma. Am J Surg Pathol. 1986 Nov. 10(11):771-9. [Medline].
Enepekides DJ. Sinonasal undifferentiated carcinoma: an update. Curr Opin Otolaryngol Head Neck Surg. 2005 Aug. 13(4):222-5. [Medline].
Cerilli LA, Holst VA, Brandwein MS, Stoler MH, Mills SE. Sinonasal undifferentiated carcinoma: immunohistochemical profile and lack of EBV association. Am J Surg Pathol. 2001 Feb. 25(2):156-63. [Medline].
Mendenhall WM, Mendenhall CM, Riggs CE Jr, Villaret DB, Mendenhall NP. Sinonasal undifferentiated carcinoma. Am J Clin Oncol. 2006 Feb. 29(1):27-31. [Medline].
Hyams VJ. Olfactory neuroblastoma (case 6). Batsakis JG, Hyams VJ, Morales AR, eds. Specifial tumors of the head and neck. Chicago: American Society of Clinical Pathologist Press; 1992. 24-29.
Malouf GG, Casiraghi O, Deutsch E, Guigay J, Temam S, Bourhis J. Low- and high-grade esthesioneuroblastomas display a distinct natural history and outcome. Eur J Cancer. 2013 Apr. 49(6):1324-34. [Medline].
Dulguerov P, Calcaterra T. Esthesioneuroblastoma: the UCLA experience 1970-1990. Laryngoscope. 1992 Aug. 102(8):843-9. [Medline].
Folbe A, Herzallah I, Duvvuri U, et al. Endoscopic endonasal resection of esthesioneuroblastoma: a multicenter study. Am J Rhinol Allergy. 2009 Jan-Feb. 23(1):91-4. [Medline].
Devaiah AK, Andreoli MT. Treatment of esthesioneuroblastoma: a 16-year meta-analysis of 361 patients. Laryngoscope. 2009 Jul. 119(7):1412-6. [Medline].
Dulguerov P, Allal AS, Calcaterra TC. Esthesioneuroblastoma: a meta-analysis and review. Lancet Oncol. 2001 Nov. 2(11):683-90. [Medline].
Loy AH, Reibel JF, Read PW, et al. Esthesioneuroblastoma: continued follow-up of a single institution’s experience. Arch Otolaryngol Head Neck Surg. 2006 Feb. 132(2):134-8. [Medline].
Dauer EH, Lewis JE, Rohlinger AL, Weaver AL, Olsen KD. Sinonasal melanoma: a clinicopathologic review of 61 cases. Otolaryngol Head Neck Surg. 2008 Mar. 138(3):347-52. [Medline].
Mendenhall WM, Amdur RJ, Hinerman RW, Werning JW, Villaret DB, Mendenhall NP. Head and neck mucosal melanoma. Am J Clin Oncol. 2005 Dec. 28(6):626-30. [Medline].
Lund VJ, Howard DJ, Harding L, Wei WI. Management options and survival in malignant melanoma of the sinonasal mucosa. Laryngoscope. 1999 Feb. 109(2 Pt 1):208-11. [Medline].
Wagner M, Morris CG, Werning JW, Mendenhall WM. Mucosal melanoma of the head and neck. Am J Clin Oncol. 2008 Feb. 31(1):43-8. [Medline].
Hillstrom RP, Zarbo RJ, Jacobs JR. Nerve sheath tumors of the paranasal sinuses: electron microscopy and histopathologic diagnosis. Otolaryngol Head Neck Surg. 1990 Mar. 102(3):257-63. [Medline].
Hicks J, Flaitz C. Rhabdomyosarcoma of the head and neck in children. Oral Oncol. 2002 Jul. 38(5):450-9. [Medline].
Hawkins WG, Hoos A, Antonescu CR, et al. Clinicopathologic analysis of patients with adult rhabdomyosarcoma. Cancer. 2001 Feb 15. 91(4):794-803. [Medline].
Fyrmpas G, Wurm J, Athanassiadou F, et al. Management of paediatric sinonasal rhabdomyosarcoma. J Laryngol Otol. 2009 Sep. 123(9):990-6. [Medline].
Raney RB, Meza J, Anderson JR, et al. Treatment of children and adolescents with localized parameningeal sarcoma: experience of the Intergroup Rhabdomyosarcoma Study Group protocols IRS-II through -IV, 1978-1997. Med Pediatr Oncol. 2002 Jan. 38(1):22-32. [Medline].
Herve S, Abd Alsamad I, Beautru R, et al. Management of sinonasal hemangiopericytomas. Rhinology. 1999 Dec. 37(4):153-8. [Medline].
Vidal RW, Devaney K, Ferlito A, Rinaldo A, Carbone A. Sinonasal malignant lymphomas: a distinct clinicopathological category. Ann Otol Rhinol Laryngol. 1999 Apr. 108(4):411-9. [Medline].
Greene FL, Page DL, Fleming ID, et al. eds. Nasal cavity and paranasalsinues. AJCC Cancer Staging Manual. New York: Springer – Verlga; 2002. 6: 59-67.
Hojo H, Zenda S, Akimoto T, et al. Impact of early radiological response evaluation on radiotherapeutic outcomes in the patients with nasal cavity and paranasal sinus malignancies. J Radiat Res. 2012 Sep. 53(5):704-9. [Medline]. [Full Text].
Swegal W, Koyfman S, Scharpf J, et al. Endoscopic and open surgical approaches to locally advanced sinonasal melanoma: comparing the therapeutic benefits. JAMA Otolaryngol Head Neck Surg. 2014 Sep. 140 (9):840-5. [Medline].
Hadad G, Bassagasteguy L, Carrau RL, et al. A novel reconstructive technique after endoscopic expanded endonasal approaches: vascular pedicle nasoseptal flap. Laryngoscope. 2006 Oct. 116(10):1882-6. [Medline].
Nicolai P, Battaglia P, Bignami M, et al. Endoscopic surgery for malignant tumors of the sinonasal tract and adjacent skull base: a 10-year experience. Am J Rhinol. 2008 May-Jun. 22(3):308-16. [Medline].
Lund V, Howard DJ, Wei WI. Endoscopic resection of malignant tumors of the nose and sinuses. Am J Rhinol. 2007 Jan-Feb. 21(1):89-94. [Medline].
Lee NY, Le QT. New developments in radiation therapy for head and neck cancer: intensity-modulated radiation therapy and hypoxia targeting. Semin Oncol. 2008 Jun. 35(3):236-50. [Medline]. [Full Text].
Chen AM, Daly ME, Bucci MK, et al. Carcinomas of the paranasal sinuses and nasal cavity treated with radiotherapy at a single institution over five decades: are we making improvement?. Int J Radiat Oncol Biol Phys. 2007 Sep 1. 69(1):141-7. [Medline].
Hoppe BS, Stegman LD, Zelefsky MJ, et al. Treatment of nasal cavity and paranasal sinus cancer with modern radiotherapy techniques in the postoperative setting–the MSKCC experience. Int J Radiat Oncol Biol Phys. 2007 Mar 1. 67(3):691-702. [Medline].
Daly ME, Chen AM, Bucci MK, et al. Intensity-modulated radiation therapy for malignancies of the nasal cavity and paranasal sinuses. Int J Radiat Oncol Biol Phys. 2007 Jan 1. 67(1):151-7. [Medline].
Patel SG, Singh B, Polluri A, et al. Craniofacial surgery for malignant skull base tumors: report of an international collaborative study. Cancer. 2003 Sep 15. 98(6):1179-87. [Medline].
Suarez C, Ferlito A, Lund VJ, et al. Management of the orbit in malignant sinonasal tumors. Head Neck. 2008 Feb. 30(2):242-50. [Medline].
Ricardo L Carrau, MD, FACS Professor, Department of Otolaryngology-Head and Neck Surgery, Director of the Comprehensive Skull Base Surgery Program, Wexner Medical Center at The Ohio State University
Ricardo L Carrau, MD, FACS is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, American College of Surgeons, American Head and Neck Society, American Laryngological Association, American Medical Association, American Rhinologic Society, North American Skull Base Society, Triological Society, Pennsylvania Medical Society
Disclosure: Nothing to disclose.
Yew Kwang Ong, MBBCh Consultant, Department of Otolaryngology, National Hospital, Singapore
Yew Kwang Ong, MBBCh is a member of the following medical societies: American Rhinologic Society, North American Skull Base Society
Disclosure: Nothing to disclose.
C Arturo Solares, MD, FACS Associate Professor of Otolaryngology-Head and Neck Surgery and Neurosurgery, Co-Director, Center for Skull Base Surgery, Georgia Regents University
C Arturo Solares, MD, FACS is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, American College of Surgeons, American Rhinologic Society, Triological Society
Disclosure: Nothing to disclose.
Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference
Disclosure: Received salary from Medscape for employment. for: Medscape.
Nader Sadeghi, MD, FRCSC Professor and Chairman, Department of Otolaryngology-Head and Neck Surgery, McGill University Faculty of Medicine; Chief Otolaryngologist, MUHC; Director, McGill Head and Neck Cancer Program, Royal Victoria Hospital, Canada
Nader Sadeghi, MD, FRCSC is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, American Head and Neck Society, American Thyroid Association, Royal College of Physicians and Surgeons of Canada
Disclosure: Nothing to disclose.
Arlen D Meyers, MD, MBA Professor of Otolaryngology, Dentistry, and Engineering, University of Colorado School of Medicine
Arlen D Meyers, MD, MBA is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, American Head and Neck Society
Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Cerescan;RxRevu;Cliexa;Preacute Population Health Management;The Physicians Edge<br/>Received income in an amount equal to or greater than $250 from: The Physicians Edge, Cliexa<br/> Received stock from RxRevu; Received ownership interest from Cerescan for consulting; for: Rxblockchain;Bridge Health.
William M Lydiatt, MD, FACS Head and Neck Surgical Oncologist, Methodist Estabrook Cancer Center; Chair-Elect, Department of Surgery, Nebraska Methodist Hospital; Clinical Professor, Department of Surgery, Creighton University School of Medicine; Lecturer, Department of Biology, University of Nebraska-Omaha
William M Lydiatt, MD, FACS is a member of the following medical societies: Alpha Omega Alpha, American Academy of Otolaryngology-Head and Neck Surgery, American College of Surgeons, American Head and Neck Society
Disclosure: Nothing to disclose.
Malignant Tumors of the Nasal Cavity
Research & References of Malignant Tumors of the Nasal Cavity|A&C Accounting And Tax Services
Source
0 Comments